Stock IOBT IO BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases IO Biotech, Inc.

Equities

IOBT

US4497781090

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
1.17 USD 0.00% Intraday chart for IO Biotech, Inc. -1.68% -37.77%
05-15 HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating MT
05-14 IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IO Biotech : Corporate Deck June 2024
PU
IO Biotech : Corporate Deck June 2024
PU
IO Biotech to Present at Jefferies Global Healthcare Conference
AQ
IO Biotech : Corporate Deck May 2024
PU
IO Biotech : Corporate Deck May 2024
PU
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
AQ
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
IO Biotech : Corporate Deck April 2024
PU
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
AQ
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
AQ
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
AQ
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
IO Biotech : Corporate Deck March 2024
PU
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
AQ
IO Biotech to Present at 44th Annual Cowen Health Care Conference
AQ
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
AQ
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
AQ
IO Biotech Announces 2023 Third Quarter Results
AQ
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
AQ
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IOBT Stock
  4. News IO Biotech, Inc.
  5. Press Releases